http://www.pharmexec.com/pharmexec The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose of news and features from the world of pharma business and marketing. 2012-05-16T23:55:21Z http://www.pharmexec.com/pharmexec/Top+Feature/Comparative-Effectiveness-Research-Challenges-for-/ArticleStandard/Article/detail/772674?ref=25 Switching Rx drugs to OTC and adding comparative data could broaden access to treatment, writes Jill Wechsler. 2012-05-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192012/772674/hurdle_176_flash.jpg HTML http://www.pharmexec.com/pharmexec/DSM---Pharm-Execs-2012-Top-50-Pharma-Companies/ArticleStandard/Article/detail/772386?ref=25 DSM - Pharm Exec's 2012 Top 50 Pharma Companies 2012-05-07T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192012/772386null HTML http://www.pharmexec.com/pharmexec/Noteworthy/Polish-Bid-for-Biotech-Glory/ArticleStandard/Article/detail/772772?ref=25 Poland's government is aiming to make the Eastern European country a biotech powerhouse. 2012-05-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192012/772772/Poland_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192012/772772null XML http://www.pharmexec.com/pharmexec/Regulatory/Government-Big-Pharmas-Best-Friend-in-Emerging-Mar/ArticleStandard/Article/detail/773570?ref=25 To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition to governments. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773570null XML http://www.pharmexec.com/pharmexec/Technology/Pharmas-Winning-Innovative-Technology/ArticleStandard/Article/detail/773559?ref=25 Highlighting the companies awarded for exemplifying a high level of operational excellence with technology. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773559null XML http://www.pharmexec.com/pharmexec/Strategy/Value-Based-Pricing-Too-High-a-Price-for-UK-Pharma/ArticleStandard/Article/detail/773567?ref=25 Changes to the P&R system in the UK could finally put some real metrics behind the elusive concept of value—but with payers clearly in the driver's seat, who needs clarity? 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773567null XML http://www.pharmexec.com/pharmexec/Marketing/Best-Practices-Commercial-Analytics/ArticleStandard/Article/detail/773564?ref=25 If the relationship between marketers and commercial analytics is leveraged properly, it can help marketers make more informed strategic decisions for their brands. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773564null XML http://www.pharmexec.com/pharmexec/R%26D/Managing-Information-Overload/ArticleStandard/Article/detail/773565?ref=25 Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773565null XML http://www.pharmexec.com/pharmexec/From+the+Editor/Seeding-Beyond-the-Base/ArticleStandard/Article/detail/773563?ref=25 The industry's reputation as a growth industry no one wants to pay for is more secure than ever. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773563null XML http://www.pharmexec.com/pharmexec/Country+Reports/Country-Report-South-Africa/ArticleStandard/Article/detail/773568?ref=25 In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773568null XML http://www.pharmexec.com/pharmexec/Top+Feature/Pharm-Exec-50-Growth-from-the-Bottom-Up/ArticleStandard/Article/detail/773562?ref=25 More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773562/pharma_50_176_flash.jpg XML http://www.pharmexec.com/pharmexec/Back+Page/Comparing-Apples-to-Broccoli/ArticleStandard/Article/detail/773571?ref=25 In late March, the Supreme Court debated the merits—or lack thereof—of the Obama Administration's Patient Protection and Affordable Care Act. Can you match the analogy with the Justice? 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773571null XML http://www.pharmexec.com/pharmexec/Article/Super-Size-Me/ArticleStandard/Article/detail/773569?ref=25 Finding opportunities in the information explosion: big data, big challenges and big rewards. 2012-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202012/773569null XML http://www.pharmexec.com/pharmexec/Noteworthy/Emerging-Markets-Whats-Your-Corporate-Value-Propos/ArticleStandard/Article/detail/771147?ref=25 Pharma companies entering the emerging markets are under pressure to offer a convincing Corporate Value Proposition (CVP). 2012-04-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182012/771147/shangai_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Technology/Establishing-Case-Quality-Metrics/ArticleStandard/Article/detail/771139?ref=25 Defining and using quality metrics for adverse events case processing. 2012-04-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182012/771139null HTML http://www.pharmexec.com/pharmexec/Noteworthy/EU-Responds-to-Troubled-Medical-Devices-Sector/ArticleStandard/Article/detail/770629?ref=25 EU health ministers have stepped carefully around the medical devices sector, but the recent scandal concerning breast implants has the European Parliament baying for action. 2012-04-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172012/770629/Europe_flag_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172012/770629null HTML http://www.pharmexec.com/pharmexec/Noteworthy/Sales-Reps-v-Pharma-The-Overtime-Issue/ArticleStandard/Article/detail/770624?ref=25 The Supreme Court's Decision on whether pharma sales reps should qualify for the 'outside sales exemption' could have far reaching implications, write Lisa A. Schreter and Kimberly J. Gost. 2012-04-25T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172012/770624/SupremeCourtMain_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/Succeeding-in-Pharma-as-a-Woman-or-Minority-Profes/ArticleStandard/Article/detail/770391?ref=25 Broaden your industry exposure. Think beyond yourself... Timely advice from this year's HBA Woman of the Year, Carolyn Buck Luce. 2012-04-24T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172012/770391/Buck-luce_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/IP-Time-for-a-Reset/ArticleStandard/Article/detail/767643?ref=25 IP must adapt to new ways of extracting value from assets the industry never knew it had, writes William Looney. 2012-04-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767643/reset_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/Fighting-the-Pain-in-Spain-and-Beyond/ArticleStandard/Article/detail/767157?ref=25 Pharm Exec talks to Carlos Plata, Chief Scientific Officer of Esteve, the Spanish company that is rising above the economic gloom to become a major player in pain. 2012-04-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767157/ESTEVE-headquarters-120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767157/ESTEVE-headquarters-176_flash.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/China-New-Opportunities-for-Growth/ArticleStandard/Article/detail/770394?ref=25 China's drug-distribution network has been a mess for years, but reforms are unveiling new opportunities for market order and growth, writes Jane Wan. 2012-04-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172012/770394/PT0412_China_web_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172012/770394null XML http://www.pharmexec.com/pharmexec/Back+Page/Scotland-Independence-and-Pharma/ArticleStandard/Article/detail/767906?ref=25 What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK? 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767906/ScotlandFlag_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767906null XML http://www.pharmexec.com/pharmexec/Noteworthy/Pharm-Exec-Ad-Stars-2012/ArticleStandard/Article/detail/767910?ref=25 This year's Ad Stars embrace creativity through the eyes of the patients. Ben Comer and Jennifer Ringler report. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767910/Ad_stars_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767910null XML http://www.pharmexec.com/pharmexec/Whitepaper/Achieving-Excellence-in-Marketing-Operations-br-/ArticleStandard/Article/detail/766211?ref=25 This white paper describes three essential capabilities for life sciences organizations that want to execute precise marketing programs on time and within budget, and effectively measure the success of those marketing investments. Three areas of focus include automated campaign management, marketing operations management and real-time decision management. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766211null REMOTE http://www.pharmexec.com/pharmexec/Regulatory/Providing-Access-Now/ArticleStandard/Article/detail/767909?ref=25 While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767909/access_traffic-light_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767909null XML http://www.pharmexec.com/pharmexec/Executive+Profiles/Emerging-Markets-Setting-a-New-Agenda/ArticleStandard/Article/detail/767911?ref=25 India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767911/Mashelkar-Photo_176_flash.jpg XML http://www.pharmexec.com/pharmexec/Washington+Report/Shortages-and-Sunshine/ArticleStandard/Article/detail/767902?ref=25 Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767902null XML http://www.pharmexec.com/pharmexec/Noteworthy/Sunshine-Act-Still-in-the-Shade/ArticleStandard/Article/detail/767901?ref=25 Phase in of the Sunshine Act will force a reconsideration of the ethical consequences of all types of pharma meetings. How and to what extent remains to be seen. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767901/Desert-sun_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Country+Reports/Country-Report-Ukraine/ArticleStandard/Article/detail/767903?ref=25 Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767903null XML http://www.pharmexec.com/pharmexec/Strategy/Navigating-MampA-Complexities/ArticleStandard/Article/detail/767905?ref=25 Too often in M&A or product-linked carve-outs, executives overlook the complexities of disentangling operations and the effort required for regulatory re-registration and labeling changes. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767905null XML http://www.pharmexec.com/pharmexec/From+the+Editor/IP-Time-for-a-Reset/ArticleStandard/Article/detail/767904?ref=25 Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767904null XML http://www.pharmexec.com/pharmexec/E-Marketing/Think-Digital-First/ArticleStandard/Article/detail/767907?ref=25 While what is considered 'traditional' marketing has evolved over the years, it's clear that a digital strategy is an absolute necessity to compete today—not just tomorrow. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767907null XML http://www.pharmexec.com/pharmexec/Meetings/Medical-Meetings-Docs-Speak-Out/ArticleStandard/Article/detail/768096?ref=25 Three physicians took the stage at the fourth annual West Coast Life Sciences Meeting Management Forum to explain to pharma and life sciences planners their perspective on healthcare reform, online versus live education, and what it takes to get them to participate in medical meetings in today's increasingly transparent environment. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/768096null XML http://www.pharmexec.com/pharmexec/COVER+STORY/HBA-Woman-of-the-Year-2012/ArticleStandard/Article/detail/767908?ref=25 Throughout her life, HBA Woman of the Year Carolyn Buck-Luce has made progress by recognizing that when one door closes, another one opens. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142012/767908/Buck-luce_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Whitepaper/Analytics-Driven-Marketing-Strategy-and-Planning-b/ArticleStandard/Article/detail/766207?ref=25 This white paper explains five ways life sciences organizations use analytics to improve ROI from sales and marketing dollars. Areas of focus include optimizing the marketing mix across groups, channels and frequency of contact as well as targeting higher value segments, identifying key opinion leaders and better understanding brand sentiment. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766207null REMOTE http://www.pharmexec.com/pharmexec/Whitepaper/Analytics-in-Managed-Markets-Negotiate-Like-a-Pro/ArticleStandard/Article/detail/766209?ref=25 This white paper reveals why analytics is the secret ingredient to achieving success in managed markets and explains why new legislation and other market factors have increased the risks of continuing business as usual. It then explains how you can set the stage for analytics by building the right infrastructure. 2012-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766209null REMOTE http://www.pharmexec.com/pharmexec/SAS---Analytics-in-Managed-Markets-Negotiate-Like-/ArticleStandard/Article/detail/766160?ref=25 SAS - Analytics in Managed Markets: Negotiate Like a Pro 2012-03-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766160null HTML http://www.pharmexec.com/pharmexec/SAS---Analytics-Driven-Marketing-Strategy-and-Plan/ArticleStandard/Article/detail/766159?ref=25 SAS - Analytics-Driven Marketing Strategy and Planning: Five Ways Life Sciences Organizations Can Use Analytics to Improve ROI from Every Sales and Marketing Dollar 2012-03-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766159null HTML http://www.pharmexec.com/pharmexec/SAS---Achieving-Excellence-in-Marketing-Operations/ArticleStandard/Article/detail/766163?ref=25 SAS - Achieving Excellence in Marketing Operations 2012-03-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766163null HTML http://www.pharmexec.com/pharmexec/Noteworthy/Does-Your-Portfolio-Review-Reflect-What-the-Patien/ArticleStandard/Article/detail/766122?ref=25 The quest for 'radical' R&D innovation is often pursued at the expense of treatments with hidden blockbuster potential, writes Bert Spilker. 2012-03-27T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766122/bert_Spilker_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766122/bert.s2_flash.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/Europe-A-Pharma-Armistice/ArticleStandard/Article/detail/765954?ref=25 Manufacturers, wholesalers, pharmacists and even parallel importers are uniting under a common blanket, writes Reflector. 2012-03-26T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/765954/Europe-flag-007_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Strategy/Novartis-LEADing-in-Emerging-Markets/ArticleStandard/Article/detail/764163?ref=25 With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition. 2012-03-12T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764163/Jimenez_120_art_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Noteworthy/Conducting-Clinical-Trials-in-China-mdash-Lessons-/ArticleStandard/Article/detail/763974?ref=25 R. Stephen Porter of VDDI Pharmaceuticals and Dragon Bio-Consultants shares his expertise with us in this exclusive podcast. 2012-03-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/763974/shangai_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/Staff-Training-Alternatives-to-the-Classroom/ArticleStandard/Article/detail/764041?ref=25 Mark McClelland and Candida Chandorkar outline how organizations sector can improve their continuing professional development and effectiveness at work. 2012-03-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764041/training_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764041null HTML http://www.pharmexec.com/pharmexec/Technology/NNITs-GxP-Cloud-Now-Offers-SaaS/ArticleStandard/Article/detail/763788?ref=25 NNIT's GxP Cloud Now Offers SaaS 2012-03-08T05:00:00Z HTML http://www.pharmexec.com/pharmexec/Noteworthy/Only-Connect-Finding-the-Key-to-Digital-Marketing/ArticleStandard/Article/detail/763590?ref=25 Jim Currie and Baber Ghauri talk to Pharm Exec about making connections that resonate with audiences in a digital world. 2012-03-07T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/763590/Digital_technology_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/How-the-Healthcare-Industry-Learned-to-Stop-Worryi/ArticleStandard/Article/detail/763070?ref=25 Embracing 'disruptive' digital technology. 2012-03-05T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/763070/doc_online_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/PE-Emedia-Rates-2012/ArticleStandard/Article/detail/763868?ref=25 PE Emedia Rates 2012 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/763868null PDF http://www.pharmexec.com/pharmexec/PE-EMedia-Kit-2012/ArticleStandard/Article/detail/766446?ref=25 PE Emedia Kit 2012 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/132012/766446null PDF http://www.pharmexec.com/pharmexec/Washington+Report/When-Talk-is-Not-So-Cheap/ArticleStandard/Article/detail/764166?ref=25 FDA and industry are pushing user fees, while they struggle with curbs on communications. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764166null XML http://www.pharmexec.com/pharmexec/Legal/Judging-a-Pill-by-its-Cover/ArticleStandard/Article/detail/764164?ref=25 Pharmaceutical trade dres is an effective marketing tool that helps boost product recognition for consumers. It's worth protecting. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764164null XML http://www.pharmexec.com/pharmexec/Noteworthy/Securing-the-Pharma-Supply-Chain-Latest-Initiative/ArticleStandard/Article/detail/765167?ref=25 The problem of supply-chain security has taken center stage with a number of recent initiatives, writes Patricia Van Arnum. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122012/765167/Approval-stamp_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122012/765167null HTML http://www.pharmexec.com/pharmexec/Strategy/The-Life-Science-of-Digital-Connections/ArticleStandard/Article/detail/764165?ref=25 Making real connections that resonate with audiences in a digital world is a fine art, especially in the heavily regulated world of Big Pharma 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764165null XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Unlocking-Value/ArticleStandard/Article/detail/764158?ref=25 Value analysis should be considered a journey, not a destination, writes Paolo De Marino. Here, he explains the principles and pitfalls of 'value segmentation'. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764158/key_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Strategy/Off-the-Hook-Pharm-Execs-Annual-Press-Audit/ArticleStandard/Article/detail/764160?ref=25 Our annual press audit finds that the big news in 2011 for pharma was ... no news. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764160/pharma_&_press_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/From+the+Editor/The-Maestros/ArticleStandard/Article/detail/764159?ref=25 Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764159null XML http://www.pharmexec.com/pharmexec/Noteworthy/Managed-Access-in-the-UK-Meeting-Unmet-Need/ArticleStandard/Article/detail/762614?ref=25 Simon Estcourt assesses how the regulatory landscape for managed access programs is evolving, particularly in the UK. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092012/762614/Patient_120x90_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092012/762614null HTML http://www.pharmexec.com/pharmexec/Back+Page/The-Big-Data-Drawback/ArticleStandard/Article/detail/764161?ref=25 In the rush to collect as much patient data as possible, are we sacrificing quality for quantity? Ben Comer reports. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764161/old-world-map-120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Regulatory/How-Can-We-Fix-the-FDA/ArticleStandard/Article/detail/764162?ref=25 How can we better balance addressing medical needs with ensuring that new drugs are safe and effective? Ron Cohen reports. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764162/ron_cohen_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/The-Italians-Job/ArticleStandard/Article/detail/764157?ref=25 After his predecessor and countryman left the EMA in disgrace, Guido Rasi jumps in as executive director—with great challenges ahead. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764157null XML http://www.pharmexec.com/pharmexec/Outsourcing/Profound-Changes-in-the-Outsourcing-Landscape/ArticleStandard/Article/detail/762383?ref=25 Sponsor sourcing requirements are diverging from the operating needs and long-term strategies of the major CROs. 2012-02-29T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092012/762383/Desert-sun-landscape_120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/Pharma-Worst-Hit-by-Talent-Crunch/ArticleStandard/Article/detail/761764?ref=25 A recent global CEO report reveals that 51% of pharma CEOs think it has become more difficult to hire workers within the sector, outweighing the same problem in all other industries surveyed. 2012-02-24T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761764/training-120.jpg_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/Biomanufacturing-Outlook-2012/ArticleStandard/Article/detail/761737?ref=25 Preliminary results from BioPlan Associates' 9th Annual Report and Survey of Biomanufacturing suggest there's a good reason to be optimistic about 2012. 2012-02-24T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761737/Eric_Langer.120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761737null XML http://www.pharmexec.com/pharmexec/Noteworthy/Preparing-For-the-New-China/ArticleStandard/Article/detail/761512?ref=25 China's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt. 2012-02-23T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761512/china-national-flag_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761512null XML http://www.pharmexec.com/pharmexec/Noteworthy/AstraZenecas-Real-World-Bet/ArticleStandard/Article/detail/761326?ref=25 In establishing the value of new medicines, old-way theory is yielding to real-world practice — but there are risks in being 'of the moment'. 2012-02-22T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761326/casino-roulette.120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Sales/Sales-Fully-Mobilize-Your-Mobile-Technology/ArticleStandard/Article/detail/758963?ref=25 So far companies have only scratched the surface of the potential offered by the 'new mobile ecosystem', writes Neeraj Singhal. 2012-02-16T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072012/758963/Neeraj-Singhal-120_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Noteworthy/The-Italians-Job-mdash-Guido-Rasis-EMA-Challenge/ArticleStandard/Article/detail/758713?ref=25 Guido Rasi, the European Medicine Association's new executive director, faces many challenges, says Reflector, not least shaking off the legacy of his early predecessor, Duilio Poggiolini. 2012-02-14T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072012/758713/Rasi_Guido-.jpg_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072012/758713null HTML http://www.pharmexec.com/pharmexec/Noteworthy/Video-GSK-Upbeat-in-Fourth-Quarter-Review/ArticleStandard/Article/detail/758580?ref=25 GSK CEO Witty sees R&D progress and opportunities amid patent expirations. Watch our exclusive video blog. 2012-02-13T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072012/758580/GSK_building_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072012/758580null HTML http://www.pharmexec.com/pharmexec/Noteworthy/FDA-Unveils-Guidance-for-Biosimilar-Development/ArticleStandard/Article/detail/758411?ref=25 After months of anticipation, FDA finally issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies. 2012-02-10T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/758411/fda.jpg_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/758411null HTML http://www.pharmexec.com/pharmexec/Article/HCP-Givaways-Get-Real/ArticleStandard/Article/detail/758472?ref=25 The Patient Protection and Affordable Care Act (?PPACA?) requires manufacturers to record, aggregate and report to the federal government ?payments and other transfers of value? to a covered recipient. This article will focus on the two key convention-related items under PPACA: food and educational products. 2012-02-10T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/758472null HTML http://www.pharmexec.com/pharmexec/Top+Feature/India-to-Double-Pharmaceutical-Exports-by-2014/ArticleStandard/Article/detail/757923?ref=25 With the $12-billion valued Indian pharma industry expected to grow at a CAGR of 16%, the Indian government plans to capitalize on the growth potential in an effort to beat the competition. 2012-02-02T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757923/India-flag-top-feature_flash.jpg XML http://www.pharmexec.com/pharmexec/Agency+Insight/Marketing-Finding-that-Perfect-Pitch/ArticleStandard/Article/detail/757965?ref=25 A good creative brief takes raw information and makes it come alive, write Al Topin and Abby Mansfield. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757965/patient-jump-120x90_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757965null XML http://www.pharmexec.com/pharmexec/Legal/Money-for-Nothing-Patents-for-Free/ArticleStandard/Article/detail/757958?ref=25 State tech transfer laws giving universities automatic ownership of employees' inventions represent a threat to pharma partnerships—but the Supreme Court is poised to intervene in the industry's favor. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757958/copyright_thumbnail.jpeg XML http://www.pharmexec.com/pharmexec/Noteworthy/Outsourcing-Strategies-for-Preferred-Provider-Part/ArticleStandard/Article/detail/758875?ref=25 As pharma increases its level of outsourcing, its models for partnering are evolving. The highly collaborative preferred-provider relationships, for example. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072012/758875/hand-shake-120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Country+Reports/Brazil-Report-A-Bold-Player-Blooms/ArticleStandard/Article/detail/757959?ref=25 Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757959null XML http://www.pharmexec.com/pharmexec/Country+Reports/Trying-Trials-at-GC-2/ArticleStandard/Article/detail/757962?ref=25 Brazil's clinical trial research is the country's backbone. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757962null XML http://www.pharmexec.com/pharmexec/Back+Page/FDA-Social-Media-Guidelines-Irresponsible/ArticleStandard/Article/detail/757971?ref=25 After two years of waiting, FDA issued the first in a series of planned guidelines on social media at the end of last year. We look at some of the experts' reactions. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757971/Social_media.120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Country+Reports/Of-Farms-Beaches-hellip-and-Generics/ArticleStandard/Article/detail/757970?ref=25 Brazilian industry is learning to spread its pharma manufacturing around more. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757970null XML http://www.pharmexec.com/pharmexec/Product+Spotlight/Brand-of-the-Year-Humira/ArticleStandard/Article/detail/757392?ref=25 Rich data on the clinical side, combined with flexible marketing and outreach to payers, have pushed Humira to the top ranks of powerhouse drugs... 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052012/757392/Humira-ProdShot-small_thumbnail.jpg HTML http://www.pharmexec.com/pharmexec/Regulatory/As-the-Compliance-Net-Tightens/ArticleStandard/Article/detail/757955?ref=25 Time to stop and think about CMS's 'Proposed Rule' on transparency and what it means for the life sciences business model. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757955/signs_caution_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757955null XML http://www.pharmexec.com/pharmexec/From+the+Editor/Brand-Success-Its-Not-Serendipity/ArticleStandard/Article/detail/757964?ref=25 A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757964/W_Looney-for-web_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757964null XML http://www.pharmexec.com/pharmexec/Strategy/Sales-Force-Survey-Still-Too-Much-Business-as-Usua/ArticleStandard/Article/detail/757953?ref=25 In the global battle for market share, the ability to adapt and mobilize your human assets around a responsive commercial model is a key variable of success. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757953/sales-survey_flash_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Country+Reports/Japanese-Knowledge-Brought-to-Brazil/ArticleStandard/Article/detail/757961?ref=25 Astellas makes its presence felt in Brazil. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757961null XML http://www.pharmexec.com/pharmexec/Noteworthy/Europes-Economic-Crisis-The-Effect-on-Outsourcing-/ArticleStandard/Article/detail/761040?ref=25 With Europe's economic troubles causing domestic profitability concerns, established pharmaceutical companies may need look to emerging markets for outsourcing partners. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761040/emerging.120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761040null XML http://www.pharmexec.com/pharmexec/Washington+Report/Costs-and-Benefits-of-Health-Reform/ArticleStandard/Article/detail/757960?ref=25 Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices? 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757960null XML http://www.pharmexec.com/pharmexec/PEGD-2012-Media-Kit/ArticleStandard/Article/detail/761114?ref=25 PEGD 2012 Media Kit 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082012/761114null PDF http://www.pharmexec.com/pharmexec/Article/Time-to-Appoint-a-Chief-Patient-Officer/ArticleStandard/Article/detail/757969?ref=25 Sarah Krug asks if it is time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757969/patient2_flash.jpg XML http://www.pharmexec.com/pharmexec/Whitepaper/Increasing-Planning-Efficiency-in-Clinical-Develop/ArticleStandard/Article/detail/756937?ref=25 Discover how leading sponsors are increasing the accuracy of their cost forecasts and reducing budget variances for clinical trials to 5% or less. Drawing on research from the Tufts Center for the Study of Drug Development and others, this white paper presents current planning trends and challenges, as well as best practices that are helping sponsor companies compress timelines and reduce cost and risk in clinical development. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042012/756937null REMOTE http://www.pharmexec.com/pharmexec/Country+Reports/How-Do-You-Make-a-Hormone/ArticleStandard/Article/detail/757968?ref=25 French-based Besins is a relatively new entrant to the Brazilian pharma market. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757968null XML http://www.pharmexec.com/pharmexec/E-Marketing/How-to-Choose-a-Medical-Animator/ArticleStandard/Article/detail/757963?ref=25 For a rendering to be effective, the right balance must be struck between captivating art and accurate science. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757963/med-animation-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757963null XML http://www.pharmexec.com/pharmexec/Strategy/Prizing-the-Eye--Brent-Saunders-CEO-Bausch---Lomb/ArticleStandard/Article/detail/757967?ref=25 Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company". 2012-02-01T05:00:00Z XML http://www.pharmexec.com/pharmexec/Professional+Marketing/Best-to-Market/ArticleStandard/Article/detail/757966?ref=25 Pharm Exec's Brand of the Year: Abbott's Humira 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757966null XML http://www.pharmexec.com/pharmexec/Country+Reports/Eenie-Meenie-Minie-Biominas/ArticleStandard/Article/detail/757954?ref=25 Biominas helps foster the development of biotech-related businesses in Brazil. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757954null XML http://www.pharmexec.com/pharmexec/Country+Reports/Torrent-Indian-Success-Brazilian-Ways/ArticleStandard/Article/detail/757957?ref=25 Torrent's affiliate in Brazil has become the India-based company's biggest. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757957null XML http://www.pharmexec.com/pharmexec/Global+Report/IndustryGovt-RampD-Support-So-Far-So-Good/ArticleStandard/Article/detail/757956?ref=25 The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757956null XML http://www.pharmexec.com/pharmexec/ClearTrial---Increasing-Planning-Efficiency-in-Cli/ArticleStandard/Article/detail/756928?ref=25 ClearTrial - Increasing Planning Efficiency in Clinical Development 2012-01-24T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/042012/756928null HTML http://www.pharmexec.com/pharmexec/Cloud-Based-Customer-Management-When-Efficiency-Re/ArticleStandard/Article/detail/756688?ref=25 Cloud-Based Customer Management: When Efficiency Reigns, Opportunities Pour 2012-01-19T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756688/John-Kelly-PfizerWEB_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756688null HTML http://www.pharmexec.com/pharmexec/Whitepaper/Physician-Targeting-and-Segmentation-Report/ArticleStandard/Article/detail/755294?ref=25 This report from the OneKey, Powered by SK&A database provides a valuable reference table with all the counts of all U.S. physicians by state and 95 medical specialties. Use this report to strategize for personal and non-personal promotions by understanding where your primary targets are located. The report, updated twice per year, also ranks the top 20 specialty areas by number of practicing physicians. 2012-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022012/755294null REMOTE http://www.pharmexec.com/pharmexec/Meeting-Global-Patient-Demand-for-Access-to-Medici/ArticleStandard/Article/detail/756689?ref=25 Meeting Global Patient Demand for Access to Medicines Prior to Approval and Launch 2012-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756689/John-Kelly-PfizerWEB_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/032012/756689null HTML http://www.pharmexec.com/pharmexec/SKampA---Physician-Targeting-and-Segmentation-Repo/ArticleStandard/Article/detail/755293?ref=25 SK&A - Physician Targeting and Segmentation Report 2012-01-09T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022012/755293null HTML